Thomas Civik's Net Worth

$5.86 Million

Estimate Recalculated Sep 8, 2024 07:40PM EST

Who is Thomas Civik?

Thomas Civik has an estimated net worth of $5.86 Million. This is based on reported shares across multiple companies, which include Repare Therapeutics Inc., Foundation Medicine, Inc., Pyxis Oncology, Inc., and FIVE PRIME THERAPEUTICS, INC..

SEC CIK

Thomas Civik's CIK is 0001723092

Past Insider Trading and Trends

2021 was Thomas Civik's most active year for acquiring shares with 3 total transactions. Thomas Civik's most active month to acquire stocks was the month of February. 2021 was Thomas Civik's most active year for disposing of shares, totalling 3 transactions. Thomas Civik's most active month to dispose stocks was the month of March. 2018 saw Thomas Civik paying a total of $2,279,312.20 for 33,421 shares, this is the most they've acquired in one year. In 2018 Thomas Civik cashed out on 33,421 shares for a total of $4,578,677.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Repare Therapeutics Inc. (RPTX) Snapshot price: $2.8

Investor

Thomas Civik owns 7,500 units of Common Shares which is worth $21,000.00. From 2021 to 2024 Thomas Civik acquired a total of 7,500 shares in Repare Therapeutics Inc. at a cost of $210,600.00.

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Jun 17
Form 4
—
0
—
—
0
Jun 8
Form 4
—
0
—
—
0
May 13
Form 4
∞
7.5K
$28.08
$210,600.00
7.5K
Nov 16
Form 4
—
0
—
—
0
Sep 7
Form 3
—
0
—
—
0
No matching records found

Foundation Medicine, Inc. No price found

Chief Commercial Officer

Thomas Civik used to own units in Common Stock but no longer holds any shares there.acquired a total of 33,421 shares in Foundation Medicine, Inc. at a cost of $2,279,312.20, Thomas also disposed a total of 33,421 shares of Foundation Medicine, Inc. equalling to $4,578,677.00.

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-33.42K
$137.00
-$4,578,677.00
0
Jul 31
Form 4
∞
33.42K
$68.20
$2,279,312.20
33.42K
Jan 1
Form 3
—
0
—
—
0
No matching records found

Pyxis Oncology, Inc. (PYXS) Snapshot price: $3.45

Investor

Thomas Civik owns 206,186 units of Common Stock which is worth $711,341.70. From 2021 to 2024 Thomas Civik acquired a total of 206,186 shares in Pyxis Oncology, Inc..

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Mar 26
Form 4
+208.52%
139.35K
—
—
206.19K
Mar 24
Form 4
∞
66.83K
—
—
66.83K
Mar 31
Form 4
∞
15.7K
$12.74
$200,018.00
15.7K
Nov 18
Form 4
—
0
—
—
0
Oct 7
Form 3
—
0
—
—
0
No matching records found

FIVE PRIME THERAPEUTICS, INC. No price found

President and CEO

Thomas Civik used to own units in Common Stock but no longer holds any shares there. In the year 2020 Thomas Civik acquired a total of 75,000 shares in FIVE PRIME THERAPEUTICS, INC., Thomas also disposed a total of 80,059 shares of FIVE PRIME THERAPEUTICS, INC. equalling to $3,041,576.72.

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-68.97K
$38.00
-$2,620,898.00
0
Apr 16
Form 4
-13.85%
-11.09K
$37.94
-$420,678.72
68.97K
Apr 9
Form 4
∞
75K
—
—
75K
Apr 13
Form 3
—
0
—
—
0
No matching records found